FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Zhou, Jinhua ^a,b,c,d,e   Wang, Yunfei ^a,b,c,d   Wang, You ^a,b   Yin, Xia ^a,b   He, Yifeng ^a,b   Chen, Lilan ^a,b   Wang, Wenwen ^a,b   Liu, Ting ^a,b   Di, Wen ^a,b,c,d  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Key Laboratory of Gynecologic Oncology   (China)

^c Focus Construction Subject of Shanghai Education Department   (China)

^d Shanghai Health Bureau Key Disciplines and Specialties Foundation   (China)

^e SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG; EXO1 PROTEIN, HUMAN; EXODEOXYRIBONUCLEASE; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; EXO1 GENE; FEMALE; GENE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; THERAPY RESISTANCE; TRANSCRIPTION REGULATION; UPREGULATION; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DNA REPAIR; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; EXODEOXYRIBONUCLEASES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; OVARIAN NEOPLASMS; OVARY; UP-REGULATION;

EID: 84901251080     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096989     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, et al. (2009) Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 27: 2686-2691.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
4. Laoukili J, Stahl M, Medema RH (2007) FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 1775: 92-102. (Pubitemid 44881197)
5. Pilarsky C, Wenzig M, Specht T, Saeger HD, Grutzmann R (2004) Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 6: 744-750. (Pubitemid 40041492)
6. Kalin TV, Wang IC, Ackerson TJ, Major ML, Detrisac CJ, et al. (2006) Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res 66: 1712-1720. (Pubitemid 43259956)
7. Kim IM, Ackerson T, Ramakrishna S, Tretiakova M, Wang IC, et al. (2006) The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res 66: 2153-2161.
8. Yoshida Y, Wang IC, Yoder HM, Davidson NO, Costa RH (2007) The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology 132: 1420-1431. (Pubitemid 46627572)
9. Kalin TV, Ustiyan V, Kalinichenko VV (2011) Multiple faces of FoxM1 transcription factor: lessons from transgenic mouse models. Cell Cycle 10: 396-405.
10. Halasi M, Gartel AL (2013) FOX(M1) news - it is cancer. Mol Cancer Ther 12: 245-254.
11. The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
12. Lok GT, Chan DW, Liu VW, Hui WW, Leung TH, et al. (2011) Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PLoS One 6: e23790.
13. Carr JR, Park HJ, Wang Z, Kiefer MM, Raychaudhuri P (2010) FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 70: 5054-5063.
14. Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, et al. (2010) FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res 8: 24-34.
15. Tran PT, Erdeniz N, Symington LS, Liskay RM (2004) EXO1-A multi-tasking eukaryotic nuclease. DNA Repair (Amst) 3: 1549-1559. (Pubitemid 39335688)
16. Eccleston J, Yan C, Yuan K, Alt FW, Selsing E (2011) Mismatch repair proteins MSH2, MLH1, and EXO1 are important for class-switch recombination events occurring in B cells that lack nonhomologous end joining. J Immunol 186: 2336-2343.
17. Sperka T, Wang J, Rudolph KL (2012) DNA damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol Cell Biol 13: 579-590.
18. Bolderson E, Tomimatsu N, Richard DJ, Boucher D, Kumar R, et al. (2010) Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. Nucleic Acids Res 38: 1821-1831.
19. Halasi M, Gartel AL (2012) Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA-damage. PLoS One 7: e31761.
20. Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, et al. (2013) Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res 19: 170-182.
21. Zhu H, Xia L, Zhang Y, Wang H, Xu W, et al. (2012) Activating transcription factor 4 confers a multidrug resistance phenotype to gastric cancer cells through transactivation of SIRT1 expression. PLoS One 7: e31431.
22. Olive PL (2011) Retention of gammaH2AX foci as an indication of lethal DNA damage. Radiother Oncol 101: 18-23.
23. Tan Y, Raychaudhuri P, Costa RH (2007) Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol 27: 1007-1016. (Pubitemid 46174563)
24. Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, et al. (2012) FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 33: 1843-1853.
25. Korver W, Roose J, Clevers H (1997) The winged-helix transcription factor Trident is expressed in cycling cells. Nucleic Acids Res 25: 1715-1719. (Pubitemid 27303351)
26. Zhao R, Han C, Eisenhauer E, Kroger J, Zhao W, et al. (2014) DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells. Mol Cancer Res 12: 370-380.
27. Zhu Z, Chung WH, Shim EY, Lee SE, Ira G (2008) Sgs1 helicase and two nucleases Dna2 and Exo1 resect DNA double-strand break ends. Cell 134: 981-994.
28. Tomimatsu N, Mukherjee B, Deland K, Kurimasa A, Bolderson E, et al. (2012) Exo1 plays a major role in DNA end resection in humans and influences double-strand break repair and damage signaling decisions. DNA Repair (Amst) 11: 441-448.
29. Myatt SS, Lam EW (2008) Targeting FOXM1. Nat Rev Cancer 8: 242.
30. Costa RH (2005) FoxM1 dances with mitosis. Nat Cell Biol 7: 108-110.
31. Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15: 2177-2196.
32. Ciccia A, Elledge SJ (2010) The DNA damage response: making it safe to play with knives. Mol Cell 40: 179-204.
33. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279. (Pubitemid 37487159)
34. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, et al. (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62: 4899-4902. (Pubitemid 34984411)
35. Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, et al. (2005) Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 327: 225-233. (Pubitemid 40051375)
36. Zhang N, Wu X, Yang L, Xiao F, Zhang H, et al. (2012) FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin Cancer Res 18: 5961-5971.
37. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, et al. (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-1883.
38. dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC (2012) Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 86: 1233-1250.
39. Ruggiero A, Trombatore G, Triarico S, Arena R, Ferrara P, et al. (2013) Platinum compounds in children with cancer: toxicity and clinical management. Anticancer Drugs 24: 1007-1019.
40. Carozzi VA, Marmiroli P, Cavaletti G (2010) The role of oxidative stress and anti-oxidant treatment in platinum-induced peripheral neurotoxicity. Curr Cancer Drug Targets 10: 670-682.